The Protocol Review and Monitoring System (PRMS) evaluates the scientific merit, quality, and progress of all cancer related clinical trials at the AECC. The functions of the PRMS are: a) to review and evaluate all protocols for scientific merit, feasibility, and quality;(b) to monitor accrual in order to assure that protocols meet their accrual goals in a timely fashion;(c) to ensure that there are no competing studies with completely overlapping eligibility, and that there is adequate justification and patient resources in circumstances where it may be desirable to have more than one protocol for a specific indication;and (d) to provide recommendations as to whether AECC investigator-initiated studies are of sufficient scientific merit to warrant allocation of Protocol Specific Research Support (PSRS) and/or other resources required for conduct of the study. The PRMS functions are carried out by the Protocol Review and Monitoring Committee (PRMC), a multidisciplinary group including pathologists, radiologists, biostatisticians, nurses, pharmacists, physician scientists from surgical, medical, pediatric, gynecological, and radiation oncology. PRMC members have experience in various therapeutic modalities (i.e., cytotoxic and targeted therapies, immunotherapy, radiation) and expertise in various stages of drug development (Phases I, II, 111 trials) and translational science. The PRMC performs a complete scientific, feasibility, and administrative review of all institutional investigator-initiated and industry-sponsored cancer related protocols. All NCI-sponsored protocols that have undergone prior peer review undergo an expedited administrative review for feasibility and overlapping eligibility with other trials.
The Protocol Review and Monitoring System (PRMS) evaluates the scientific merit, quality, prioritization, and progress of all the cancer related clinical trials at the Albert Einstein Cancer Center (AECC). As an NCI designated Cancer Center, AECC contributes to the national effort to reduce morbidity and mortality from cancer.
|Peregrina, Karina; Houston, Michele; Daroqui, Cecilia et al. (2015) Vitamin D is a determinant of mouse intestinal Lgr5 stem cell functions. Carcinogenesis 36:25-31|
|Kim, Ryung S (2015) A new comparison of nested case-control and case-cohort designs and methods. Eur J Epidemiol 30:197-207|
|Arora, Pooja; Baena, Andres; Yu, Karl O A et al. (2014) A single subset of dendritic cells controls the cytokine bias of natural killer T cell responses to diverse glycolipid antigens. Immunity 40:105-16|
|Stanley, Pamela (2014) Galectin-1 Pulls the Strings on VEGFR2. Cell 156:625-6|
|Yamane, Fumihiro; Nishikawa, Yumiko; Matsui, Kazue et al. (2014) CSF-1 receptor-mediated differentiation of a new type of monocytic cell with B cell-stimulating activity: its selective dependence on IL-34. J Leukoc Biol 95:19-31|
|Singh, M; Quispe-Tintaya, W; Chandra, D et al. (2014) Direct incorporation of the NKT-cell activator ?-galactosylceramide into a recombinant Listeria monocytogenes improves breast cancer vaccine efficacy. Br J Cancer 111:1945-54|
|Bahde, Ralf; Kapoor, Sorabh; Viswanathan, Preeti et al. (2014) Endothelin-1 receptor A blocker darusentan decreases hepatic changes and improves liver repopulation after cell transplantation in rats. Hepatology 59:1107-17|
|Ho, Gloria Y F; Wang, Tao; Zheng, Siqun L et al. (2014) Circulating soluble cytokine receptors and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 23:179-88|
|Ghartey, Jeny P; Smith, Benjamin C; Chen, Zigui et al. (2014) Lactobacillus crispatus dominant vaginal microbiome is associated with inhibitory activity of female genital tract secretions against Escherichia coli. PLoS One 9:e96659|
|Kerns, Sarah L; de Ruysscher, Dirk; Andreassen, Christian N et al. (2014) STROGAR - STrengthening the Reporting Of Genetic Association studies in Radiogenomics. Radiother Oncol 110:182-8|
Showing the most recent 10 out of 938 publications